Lovastatin, not simvastatin, corrects core phenotypes in the fragile X mouse model (2018)

First Author: Muscas M

Attributed to: Targeting ERK and mTOR for the treatment of fragile X syndrome funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/430348

Publication URI: http://dx.doi.org/10.1101/430348

Type: Preprint